Neonatal Disease — Neonatal Admission in Assuit University Children Hospital
Citation(s)
Alkiaat A, Hutchinson M, Jacques A, Sharp MJ, Dickinson JE Evaluation of the frequency and obstetric risk factors associated with term neonatal admissions to special care units. Aust N Z J Obstet Gynaecol. 2013 Jun;53(3):277-82. doi: 10.1111/ajo.12070. Epub 2013 Mar 13.
Dassios T, Greenough A, Leontiadi S, Hickey A, Kametas NA Admissions for hypoglycaemia after 35 weeks of gestation: perinatal predictors of cost of stay. J Matern Fetal Neonatal Med. 2019 Feb;32(3):448-454. doi: 10.1080/14767058.2017.1381905. Epub 2018 Jan 31.
Goswami IR, Ghosh JK, Sinha MK, Begum H, Chatterjee S Can the special care neonatal unit admission cut-off be lowered down to 1500g babies? Indian J Pediatr. 2009 Sep;76(9):937-9. doi: 10.1007/s12098-009-0185-z. Epub 2009 Nov 4.
Seid SS, Ibro SA, Ahmed AA, Olani Akuma A, Reta EY, Haso TK, Fata GA Causes and factors associated with neonatal mortality in Neonatal Intensive Care Unit (NICU) of Jimma University Medical Center, Jimma, South West Ethiopia. Pediatric Health Med Ther. 2019 May 3;10:39-48. doi: 10.2147/PHMT.S197280. eCollection 2019.
Causes and Outcomes of Neonatal Admission in Neonatal Intensive Care Unit of Assuit University Children Hospital(AUCH)
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
